Effectiveness of Japanese encephalitis SA 14-14-2 live attenuated vaccine among Indian children: Retrospective 1:4 matched case-control study

Tandale, Babasaheb V.; Khan, Siraj Ahmed; Kushwaha, K. P.; Rahman, H.; Gore, Milind M.; Sapkal, Gajanan; Bondre, Vijay P.; Srivastava, Divya; Laskar, Basanta; Mahanta, Jagadish

doi:10.1016/j.jiph.2018.04.011

Cited by 27 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postmarketing surveillance by the Indian Council of Medical Research reported SCRs, 28 days postvaccination, to be 67.2% in JE-naive children alone and 73.9% overall. The vaccine effectiveness estimate is reported to be 43.8% (95% CI, 1.9–67.8) for a single dose of SA 14-14-2 [ 30 ]. Despite the vaccine being available for more than 12 years, numerous JE outbreaks were reported, affecting an increased proportion of adults and children [ 9 , 31–36 ].…”

Section: Discussionmentioning

confidence: 99%

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Vadrevu

Sriram

Khalatkar³

et al. 2019

The Journal of Infectious Diseases

View full text Add to dashboard Cite

Background This study reports immunogenicity, safety, and interchangeability of a single-dose, inactivated, Vero-cell derived, JENVAC to the live-attenuated SA 14-14-2 vaccine in healthy children. Methods This phase 4, multicenter, open-label, randomized, control trial enrolled 360 children who were equally randomized to receive a single dose of either JENVAC or SA 14-14-2. Children were followed at various time points, until 2 years (day 720) postvaccination, upon which a subset from each group was divided and allocated to a receive a booster dose or the other vaccine. Results At all time points, immunological measures were statistically higher in the JENVAC group. In the interchangeability study, children receiving 2 doses of JENVAC reported significantly higher response compared with 2 doses of SA 14-14-2. No difference in adverse events was observed. These corroborate with excellent seroprotection after the first dose of an earlier JENVAC study. Conclusions A single-dose vaccination with JENVAC induces protective titers that persist up to 1 year. We report appreciable interchangeability between both vaccines, with JENVAC/JENVAC combination exhibiting the highest immune response. JENVAC is now licensed as a single-dose Japanese encephalitis vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Vadrevu

Sriram

Khalatkar³

et al. 2019

The Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…However, infection or vaccination usually results in the generation of antibodies that cross-react with all JEV genotypes. Therefore, vaccines have been developed mainly against JEV genotype III with live attenuated or formalin-inactivated virus (e.g., IXARIO ® ), which induce long lasting immunity and are well tolerated by children and aged people [88,89,90,91,92,93,94,95]. Of note, JEV infection and vaccination may induce antibodies that are cross-reactive with other flaviviruses, including DENV [71,83,96,97].…”

Section: Immune Response and Vaccinementioning

confidence: 99%

Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading

Filgueira

Lannes

2019

Pathogens

View full text Add to dashboard Cite

Japanese encephalitis virus (JEV) is an emerging flavivirus of the Asia-Pacific region. More than two billion people live in endemic or epidemic areas and are at risk of infection. Recently, the first autochthonous human case was recorded in Africa, and infected birds have been found in Europe. JEV may spread even further to other continents. The first section of this review covers established and new information about the epidemiology of JEV. The subsequent sections focus on the impact of JEV on humans, including the natural course and immunity. Furthermore, new concepts are discussed about JEV’s entry into the brain. Finally, interactions of JEV and host cells are covered, as well as how JEV may spread in the body through latently infected immune cells and cell-to-cell transmission of virions or via other infectious material, including JEV genomic RNA.

show abstract

“…The incidence of Japanese encephalitis has however decreased in the recent years due to successful vaccination programmes in the 181 endemic districts of India, including eastern UP, Bihar, and West Bengal. 19 More recently, many other viruses like the enterovirus, Chandipura virus, Nipah virus, Zika virus, dengue virus, Chikungunya virus etc., have emerged and have been implicated in the outbreaks of AES in the Indian subcontinent. 20…”

Section: Etiologymentioning

confidence: 99%

Managing Meningoencephalitis in Indian ICU

Sapra

Singhal

2019

Indian Journal of Critical Care Medicine

View full text Add to dashboard Cite

show abstract

Effectiveness of Japanese encephalitis SA 14-14-2 live attenuated vaccine among Indian children: Retrospective 1:4 matched case-control study

Abstract: We concluded that the single subcutaneous dose of SA 14-14-2 JE vaccine provided moderate effectiveness in Indian children.

Cited by 27 publications

References 23 publications

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading

Managing Meningoencephalitis in Indian ICU

Contact Info

Product

Resources

About